Accounting for noncompliance in the design of clinical trials

Drug Information Journal

Volumn 31, Issue 1, 1997, Pages 157-165

  Albert, Jeffrey M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Clinical trials; Compliance monitoring; Intent to treat; Noncompliance; Study design

Indexed keywords

DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; HUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031053667     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159703100123     Document Type: Article

References (35)

1. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chronic Dis. 1967; 20:637-648.
2. Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials. 1987;8:12-19.
3. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. St. Louis, MO: Mosby-Year Book, Inc; 1985.
4. Foulkes MA, Ellenberg SS. Large, simple trials of HIV therapies. In: Finkelstein DM, Schoenfeld DA, Eds. AIDS Clinical Trials. New York, NY. Wiley-Liss, Inc; 1995.
5. Pullar T. Compliance with drug therapy. Br J Clin Pharmacol. 1991;32:535-539.
6. Ellenberg SS, Finkelstein DM, Schoenfeld DA. Statistical issues arising in AIDS clinical trials (with comments and rejoinder). J Am Stat Assoc. 1992; 87:562-583.
7. Freedman LS. The effect of partial noncompliance on the power of a clinical trial. Control Clin Trials. 1990;11:157-168.
8. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981;2:93-114.
9. Lachin JM, Foulkes MA. Evaluation of sample size and power for analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986; 42:507-519.
10. Pledger GW. Compliance in clinical trials: impact on design, analysis, and interpretation. In: Schmidt D. Leppik IE, Eds. Compliance in Epilepsy. Amsterdam: Elsevier Science Publishers BV; 1988.
11. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Pryzbeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
12. Taggart AJ, Johnson GD, McDevitt DG. Does the frequency of daily dosage influence compliance with digoxin therapy? Br J Clin Pharmacol. 1991;1: 31-34.
13. Lang J. The use of a run-in to enhance compliance. Stat Med. 1990;9:87-95.
14. Brittain E, Wittes J. The run-in period in clinical trials: the effect of misclassification on efficiency. Control Clin Trials. 1990;11:327-338.
15. Fletcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical setting. Arch Intern Med. 1979;139:635-638.
16. Cramer JA. Overview of methods to measure and enhance patient compliance. In: Cramer JA, Spilker B, Eds. Patient Compliance in Medical Practice and Clinical Trials. New York, Raven Press; 1991.
17. Kruse W, Nikolaus T, Rampmaier J, Weber E, Schlierf G. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol. 1993;45:211-215.
18. Young LM, Haakenson CM, Lee KK, van Eeckhout JP. Riboflavin use as a drug marker in Veterans Administration cooperative studies. Control Clin Trials. 1984;5:497-504.
19. Hardy E, Kumar S, Peaker S, Feely M, Pullar T. A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metroprolol, Meteros) in reflecting compliance by volunteers. Br J Clin Pharmacol. 1990;30:437-441.
20. Pullar T, Kumar S, Chrystyn H, Rice P, Peaker S, Feely M. The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance. Br J Clin Pharmacol. 1991;32:329-333.
21. Richardson D, Liou S-H, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117. J Acquir Immune Defic Syndr. 1993;6:1212-1223.
22. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther. 1989; 46:163-168.
23. Kish L. Survey Sampling. New York, NY, John Wiley & Sons; 1965.
24. Coronary Drug Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med. 1980;302:1038-1041.
25. Peduzzi P, Wittes J, Detre K, Holford T. Analysis as-randomized and the problem of nonadherence: an example from the Veterans Affairs randomized trial of coronary artery bypass surgery. Stat Med. 1993; 12:1185-1195.
26. Lagakos SW, Lim LL-Y, Robins JM. Adjusting for early treatment termination in comparative clinical trials. Stat Med. 1990;9:1417-1424.
27. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the multiple risk factor intervention trial. Control Clin Trials. 1993;14:79-97.
28. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Comm Stat - Theory Methods. 1991;20:2609-2631.
29. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc. 1991;86: 9-26.
30. Albert JM, DeMets DL. On a model-based approach to estimating efficacy in clinical trials. Stat Med. 1995;13:2323-2335.
31. Newcombe RG. Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur. Stat Med. 1988;7:1179-1186.
32. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Stat Med. 1991;10:45-52.
33. Dixon DO, Albert JM. Issues in the design and analysis of AIDS clinical trials. In: Thall PF, Ed. Recent Advances in Clinical Trial Design and Analysis. Norwell, MA: Kluwer Academic Publishers; 1995.
34. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med. 1991;10:1595-1605.
35. May GS, DeMets DL, Friedman LM, et al. The randomized clinical trial: bias in analysis. Circulation. 1981;64:669-673.